Why NAD+ Supplements May Miss the Problem in Diabetic Hearts
New diabetic-heart research links ACMSD to impaired NAD+ synthesis, while the only heart-failure NAD+ trial leaves HFpEF treatment unanswered in humans.
HFpEF exercise training improves fitness and quality of life, but evidence does not yet show fewer deaths or hospitalizations. Here's what the trials show.
Semaglutide Helps a Specific Kind of HFpEF—Not All
Semaglutide improved symptoms and walking capacity in obesity-related HFpEF, but the evidence does not support cardiac use for every patient—or biohacker.
GLP-1 Drugs and Heart Failure: Benefit Seems to Depend on Obesity
GLP-1 drugs cut cardiovascular death broadly, but heart failure hospitalization benefit appears limited to obese patients. Here's what the evidence shows.
GLP-1 Drugs in Heart Failure: Real Promise, Tight Limits
Meta-analyses suggest GLP-1 drugs help obese patients with HFpEF feel and function better, but no trial has shown longer survival or clear benefit in HFrEF.